NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses noteworthy research on early-relapse multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.
In one study, isatuximab plus carfilzomib and dexamethasone (Isa-Kd) outperformed carfilzomib and dexamethasone alone in patients with relapsed multiple myeloma.
“That’s not surprising at all; I think that triplets are better than doublets even in the relapse setting,” Banerjee, an assistant professor at the University of Washington, said. “Even for patients who had a lousy response to the first
